Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuroblastoma breakpoint family member 12 (NBPF12)
- Target
- NBPF12
- Molecular classification
- Other (NBPF family member, protein coding gene), Segmental duplication gene, Contains DUF1220 protein domains
01
Overview
Neuroblastoma breakpoint family member 12 is a member of the NBPF gene family, characterized by recent expansion within the primate lineage, especially humans, and by tandem repeats of the DUF1220 protein domain[3][7]. NBPF family members are primarily located in segmental duplications on chromosome 1q21.1, a chromosomal region frequently amplified in various aggressive tumors and implicated in several developmental and neurogenetic disorders. Copy number variations affecting NBPF12 and related family members have been associated with diseases such as autism, schizophrenia, neuroblastoma, and congenital anomalies. NBPF12 is not a classic receptor, enzyme, transporter, or transcription factor, but its genetic dosage and transcriptional activity contribute to important cellular and developmental processes. It is not currently a direct drug target, though the NBPF gene family plays a putative role in disease pathogenesis[1][3][4][7].
- Other names
- NBPF member 12NBPF12COAS1KIAA1245Chromosome 1 amplified sequence 1Neuroblastoma breakpoint family member 12chromosome one amplified sequence 1chromosome 1 amplified sequence 1
02
Biological functions
Likely involved in protein folding (based on predicted interactions with cyclophilin-type PPIase family proteins, but not directly established)May regulate transcription, as shown by transcription factor binding at its promoterImplicated in neural development and possibly expansion of the brain neocortex (through NBPF family roles)Biological impact through gene copy number variation on neurodevelopment and organogenesis
03
Disease associations
Cancer (notably neuroblastoma, other solid tumors, and multiple types of cancer due to 1q amplification)Developmental and neurogenetic diseases (autism, schizophrenia, cognitive disability, microcephaly, macrocephaly, congenital heart disease, congenital kidney and urinary tract anomalies)
04
Biomarkers
NBPF12 gene copy number variation (as part of chromosome 1q21.1 copy number variation syndrome)May be included in broader CNV/profiling for cancers and developmental disorders involving chromosome 1q
Beyond the preview
Go deeper on Neuroblastoma breakpoint family member 12 (NBPF12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuroblastoma breakpoint family member 12 (NBPF12).